Results 71 to 80 of about 11,103 (274)

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou   +4 more
wiley   +1 more source

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

open access: yesФармакоэкономика, 2020
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov   +2 more
doaj   +1 more source

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

open access: yes, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard   +4 more
core   +4 more sources

Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab

open access: yesAllergy, EarlyView.
Mepolizumab and omalizumab induce a distinct clinical effect. Mepolizumab and omalizumab induce both common and treatment‐specific metabolic and protein profiles over time in patients with severe asthma. Multiomic integration and receiver operating characteristic curve analyses reveal a specific set of biomolecules suggesting their value as potential ...
Nuria Contreras   +16 more
wiley   +1 more source

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

open access: yes, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source

Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score

open access: yesAllergy, EarlyView.
A retrospective cohort of newly diagnosed treatment‐naive patients with ABPA in Japan who were followed up for up to 3 years after the primary diagnosis was analyzed to explore the clinical remission rate and clinical characteristics of ABPA resistant to standard treatment or prone to exacerbation during/after treatment.
Jun Tanaka   +19 more
wiley   +1 more source

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]

open access: yes, 2017
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy   +4 more
core   +3 more sources

Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities

open access: yesAllergy, EarlyView.
ABSTRACT Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs ...
G. Walter Canonica   +9 more
wiley   +1 more source

Anaphylaxis to three humanized antibodies for severe asthma: a case study

open access: yesAllergy, Asthma & Clinical Immunology, 2020
Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo   +9 more
doaj   +1 more source

Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis

open access: yesAllergy, EarlyView.
MEPOLYP was a pooled analysis of 1037 patients with SAEP[±]CRSwNP. Mepolizumab was associated with a reduction in CSEs, OCS use, and BEC, and improved lung function and ACT score. Over 47% of patients fulfilled ≥ 3 clinical remission criteria. When compared, there was a 30.0% incremental benefit of mepolizumab in reducing CSEs for patients with SAEP ...
Florence Schleich   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy